Trial intelligence / Profile preview

Biosimilar teriparatide vs alendronate in prevention of new vertebral fractures in women at imminent fracture risk

2025-521301-40-00Phase 4Authorised

Sponsor: Gedeon Richter Plc
Start: Feb 2025
Modality: Small Molecules, Recombinant Proteins and Enzymes, Peptides
Countries: 1

Overview

Phase 4, randomised trial in osteoporosis, vertebral compression fracture (VCF) and hip fracture comparing Terrosa with alendronate (2 arms). Planned start Feb 2025; status: authorised.

Drugs

ZT-034alendronate

Conditions

osteoporosisvertebral compression fracture (VCF)hip fracture

Beyond the preview

Go deeper on 2025-521301-40-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-521301-40-00.